이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

MS-DETECT: MSCopilot®을 사용한 다발성 경화증 진행의 조기 감지 (MS-DETECT)

2026년 10월 30일 업데이트: Ad scientiam

The study aims to evaluate MSCopilot® Detect, a smartphone application for at-home monitoring of patients with Multiple Sclerosis (MS).

The primary objective is to enhance and standardize remote monitoring of MS patients to accurately assess disease progression caused by either Relapse Activity Worsening (RAW) or Progression Independent of Relapses (PIRA). The study also aims to assess the safety, usability, and satisfaction of the solution.

A secondary objective is to determine MSCopilot® Detect's ability to provide early detection of disease changes and predict changes in Expanded Disability Status Scale (EDSS) scores in more patients.

Exploratory objectives include evaluating the relationship between MSCopilot® Detect composite and individual scores and other biomarkers such as MRI, soluble glial fibrillary acidic protein (sGFAP), and soluble neurofilament light chain (sNfL).

Patients will be able to download the free MSCopilot® Detect app. They will participate in 1 inclusion visit and 3 follow-up visits, scheduled at 6 months, 12 months, and 18 months (an additional visit at 24 months may be scheduled if necessary). Every 3 months, patients will complete validated questionnaires regarding MS symptoms and quality of life and participate in digital tests designed to monitor MS symptom progression.

The study will include 336 MS patients and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France

연구 개요

상태

모집하지 않고 적극적으로

연구 유형

중재적

등록 (실제)

336

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Esbjerg, 덴마크
        • University Hospital of Southern Denmark
      • Glostrup Municipality, 덴마크
        • Finn Sellebjerg
      • Viborg, 덴마크
        • Sivagini Prakash
      • Bayreuth, 독일
        • Boris-Alexander Kallman
      • Dresden, 독일
        • Universitätsklinikum Carl Gustav Carus
      • Erbach im Odenwald, 독일
        • Rupert Knoblich
    • California
      • San Diego, California, 미국, 92093
        • Jennifer Graves
    • Georgia
      • Atlanta, Georgia, 미국, 30327
        • Joash Lazarus Sr.
    • Illinois
      • Northbrook, Illinois, 미국, 60062
        • Daniel Wynn
    • Indiana
      • Indianapolis, Indiana, 미국, 46256
        • Craig E. Herrman
    • Louisiana
      • New Orleans, Louisiana, 미국, 70121
        • Jennifer Feng
    • Missouri
      • St Louis, Missouri, 미국, 63110
        • Robert Naismith
    • Ohio
      • Columbus, Ohio, 미국, 43235
        • Aaron Boster
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • Gabriel Pardo
    • Oregon
      • Portland, Oregon, 미국, 97239-3098
        • Vijayshree Yadav
    • Texas
      • Austin, Texas, 미국, 78712
        • Leorah Freeman
      • Girona, 스페인
        • Gary Álvarez Bravo
      • Madrid, 스페인
        • University Hospital San Carlos
      • Madrid, 스페인
        • Enric Monreal
      • Málaga, 스페인
        • Ana Alonso
      • Oviedo, 스페인
        • Miguel Llaneza
      • Zaragoza, 스페인
        • Jesùs Martin
      • Florence, 이탈리아
        • Emilio Portaccio
      • Foggia, 이탈리아
        • Emanuele D'Amico
      • Milan, 이탈리아
        • IRCCS Ospedale San Raffaele
      • Burnaby, 캐나다
        • Galina Vorobeychik
      • Ottawa, 캐나다
        • Mark Freedman
      • Toronto, 캐나다
        • St. Michael's Hospital
      • Vancouver, 캐나다
        • Robert Carruthers
      • Lille, 프랑스
        • Hôpital Roger Salengro
      • Lomme, 프랑스
        • Cécile Donzé
      • Marseille, 프랑스
        • Adil Maarouf
      • Nice, 프랑스
        • Mikael Cohen
      • Rouen, 프랑스
        • Bertrand Bourre

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

30년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Adult patients living with RRMS or SPMS, aged 30 to 65
  • EDSS score between 2.5 to 6.5 points
  • With a disease duration > 5 years
  • Clinically stable during the last 3 months before inclusion (no relapses, no disability progression)
  • No change in the DMT* during the last 3 months before inclusion
  • Receiving optimal symptomatic treatments at baseline (clinician's judgment)
  • Owns a personal smartphone which mobile operating system is above 14 for IOS (iPhone) and 8 for Android included with a good internet connexion
  • Able to use a smartphone
  • Able to read language in wich the mobile application is available and able to understand pictograms.
  • Applicable to patients enrolled in France only: affiliated to a social security system.

Exclusion Criteria:

  • Medically unstable conditions that may hinder patient's ability to comply with the study procedures
  • Inability to use a smartphone or MSCopilot® Detect application
  • Patient with corrected visual acuity less than 4/10 (Monoyer) or 20/50 (Snellen at 20 feet) or +0,4 (LogMAR)
  • Pregnancy and nursing women
  • Persons under guardianship or curatorship
  • Current drugs or/and alcohol abuse that could influence performance on the tests (clinician's judgment)
  • Patients have participated in another clinical study within the previous 30 days of screening or are currently participating in another study that, in the opinion of the Investigator, might interfere with the patient's full participation in the study or confound the assessment of the patient or outcome of the study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 다른
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: MSCopilot® Detect

Performance of digital tests and standard test in clinic at D0, M6, M12, M18 and M24 (if applicable) Use of MSCopilot® Detect at-home in between visits during 18 or 24 months (if applicable)

MSCopilot® Detect includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to fatigue and Multiple Sclerosis quality of life

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
To evaluate MSCopilot® Detect individual scores and/or composite scores sensitivity to detect disability worsening based on revised-MSFC scores.
기간: Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)

The discriminatory ability of the MSCopilot® Detect application in detecting clinically meaningful worsening (disability worsening) based on the revised-MSFC will be evaluated using the Area Under the ROC Curve (AUC) method. Confidence intervals will also be estimated.

The minimum significant AUC value will be set at >0.67, and Confidence Intervals will be calculated. Sensitivity and specificity will also be determined. To validate the estimated AUC values and cutoffs generated by the MSCopilot® Detect application, a train/test set will be utilised.

Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)

2차 결과 측정

결과 측정
측정값 설명
기간
To evaluate MSCopilot® Detect individual scores and/or composite scores sensitivity to detect disability worsening based on EDSS.
기간: Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)

The study will evaluate the sensitivity, specificity, concordance, and accuracy of the MSCopilot® Detect application in predicting confirmed disability worsening (CDW) at 24 weeks as also captured by the EDSS, using a contingency table.

We will also generate time series box plots of MSCopilot® Detect individual scores and/or composite scores based on the patient progression status (determined by EDSS), using both intra-patient and inter-patient visualisation.

Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
To evaluate MSCopilot® Detect individual scores and/or composite scores sensitivity to detect disability worsening earlier than the EDSS.
기간: Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)

The time to progression-free events based on EDSS and MSCopilot® Detect individual scores and/or composite scores will be estimated with a Kaplan-Meier method (Log-rank test for comparison). Univariate and multivariate survival models (e.g. Cox or Anderson-Gill survival model), will be used to estimate Hazards Rates (HRs), if relevant.

Proportions of disability worsening based on MSCopilot® Detect composite or individual scores and worsening based on the EDSS 24-week CDW will be compared for each timepoint.

Time series boxplot of MSCopilot® Detect individual scores and/or composite score according to the patient disability worsening (by EDSS) intra-patient and inter-patient.

Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
To evaluate MSCopilot® Detect individual and/or composite scores ability to detect disease progression in absence of a relapsing activity (PIRA).
기간: Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)

Proportion of patients with PIRA (progression independent of relapses) based either on EDSS 24-week CDP compared to the proportion of patients with PIRA based on MSCopilot® Detect composite or individual scores progression status.

Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
To evaluate MSCopilot® Detect individual scores and/or composite scores ability to detect MSFC changes over time.
기간: Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)

Slopes parameters will be computed using a mix model to characterize the change from baseline in MSCopilot® Detect individual and/or composite scores and revised-MSFC scores over time.

The association between these slopes parameters will be assessed using correlation coefficient.

Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
To measure MSCopilot® Detect individual scores and/or composite scores association with the clinical scores.
기간: Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)

The association between digital and clinical scores will be studied with correlation coefficient calculated between:

  • MSCopilot® Detect individual scores ((MWPT, MDT, MCT, MVT and Mobile Walking Endurance Test (MWET)) and/or composite score at home and EDSS score performed in clinic.
  • MSCopilot® Detect individual scores (MWPT, MDT, MCT, MVT and MWET) and/or composite score at home and revised-MSFC-3 or Revised-MSFC3 + SLCLAT scores performed in clinic.
Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
To assess reproducibility of MSCopilot® Detect individual scores and/or composite scores between in-clinic and at-home digital tests.
기간: At home (Day 1, Month 6+1 day, Month 12 + 1 day, Month 18-1 day and Month 24-1 day (if applicable)) and in-clinic ((Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable))

Intraclass correlation coefficient (ICC) between MSCopilot® Detect individual scores and/or composite score at home and in-clinic.

At home (Day 1, Month 6+1 day, Month 12 + 1 day, Month 18-1 day and Month 24-1 day (if applicable)) and in-clinic ((Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable))
To assess reliability of MSCopilot® Detect individual scores and/or composite scores at-home over time.
기간: Day 0 versus Month 6, Month 6 versus Month 12, Month 12 versus Month 18, Month18 versus Month 24 (if applicable) AND Day 0 to Month 18 or Day 0 to Month 24 (if applicable) and Day 0 to Month 15 or Day 0 to Month 21 (if applicable) at home.

Intraclass correlation coefficient (ICC) of MSCopilot® Detect individual scores and/or composite score at home with a maximum paired time point of 6 months.

ICC of MSCopilot® Detect individual scores and/or composite score at home will over time.

Day 0 versus Month 6, Month 6 versus Month 12, Month 12 versus Month 18, Month18 versus Month 24 (if applicable) AND Day 0 to Month 18 or Day 0 to Month 24 (if applicable) and Day 0 to Month 15 or Day 0 to Month 21 (if applicable) at home.
To evaluate Patient QoL (Multiple Sclerosis Impact Scale: MSIS-29 and Modified Fatigue Impact Scale - 5-item version: MFIS-5) and their association with MSCopilot® Detect individual and composite scores.
기간: Throughout the study between in clinic visit, an average of 24 months

Analysis of MSIS-29 and MFIS-5 questionnaires:

Descriptive analysis of questionnaire scores over time. Comparison of Patient QoL between patients with and without a confirmed disability worsening Correlation between MSCopilot® Detect individual and/or composite score at home and Questionnaires scores (MSIS29 and MFIS-5).

Sensitivity, specificity, concordance, and accuracy will be evaluated between clinically meaningful change of MSCopilot® Detect application (individual and composite scores) and questionnaires (MSIS29 and MFIS-5).

Proportions comparison of patients with a clinically meaningful change will be assessed between MSCopilot® Detect application (individual and composite scores) and questionnaires (MSIS29 and MFIS-5).

Clinically meaningful change for questionnaires:

MSIS-29: 8-point change compared to baseline. MFIS-5: 4-point change compared to baseline.

Throughout the study between in clinic visit, an average of 24 months
To evaluate the ability of MSCopilot® Detect individual scores and/or composite score to discriminate between a relapse and a momentary disability worsening (+1 point EDSS score for an initial EDSS <5,5; +0.5 point for an initial EDSS ≥5.5).
기간: Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)

Descriptive analysis:

MSCopilot® Detect individual and/or composite score profiles, between relapse and a momentary disability worsening patient.

Annualized Relapse Rate (ARR) calculation. Logistic regression to estimate Area under ROC Curve (i.e. discriminatory power).

Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
To evaluate MSCopilot® Detect Safety
기간: Throughout the study between in clinic visit, an average of 24 months

Descriptive analysis of the number of Adverse Events related to MSCopilot® Detect will be reported.

Throughout the study between in clinic visit, an average of 24 months
To evaluate MSCopilot® Detect Adherence
기간: Throughout the study between in clinic visit, an average of 24 months

Descriptive analysis of the mobile application's adherence data (number of completed questionnaires, number of performed tests, number of performed sessions, etc.)

Throughout the study between in clinic visit, an average of 24 months
To assess the satisfaction and user experience with the MSCopilot® Detect smartphone application and the MSCopilot® Detect web dashboard.
기간: Every 3 months for about 24 months

Descriptive analysis over the course of the study of the answers to the patient satisfaction and user experience questionnaires related to the use of the MSCopilot® Detect smartphone application.

Every 3 months for about 24 months
To assess the satisfaction and user experience with the MSCopilot® Detect web dashboard.
기간: Every 6 months for about 24 months

Descriptive analysis over the course of the study of the answers to physician satisfaction & user experience questionnaires relative to the use of the MSCopilot® Detect web dashboard.

Every 6 months for about 24 months
To describe the evolution of MSCopilot® Detect individual scores and/or composite scores at-home over time.
기간: Throughout the study between in clinic visit, an average of 24 months

The time to progression-free events based on MSCopilot® Detect individual scores and/or composite scores will be estimated with a Kaplan-Meier method (Log-rank test for comparison). Univariate and multivariate survival models (e.g. Cox or Anderson-Gill survival model), will be used to estimate Hazards Rates (HRs), if relevant.

Cumulative proportions of disability worsening based on MSCopilot® Detect composite or individual scores for each timepoint.

Time series boxplot of MSCopilot® Detect individual scores and/or composite score according to the patient disability worsening (by MSCopilot® Detect) using both intra-patient and inter-patient visualisation.

Throughout the study between in clinic visit, an average of 24 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 9월 22일

기본 완료 (추정된)

2027년 5월 31일

연구 완료 (추정된)

2027년 5월 31일

연구 등록 날짜

최초 제출

2023년 3월 13일

QC 기준을 충족하는 최초 제출

2023년 4월 3일

처음 게시됨 (실제)

2023년 4월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 30일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

예

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다